Omali Pitiyarachchi

Omali Pitiyarachchi

Auto-generated profile, based on publicly available information

Omali Pitiyarachchi

School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Gynecologic Oncology
Verified
Journal Article
Open access
OPOmali Pitiyarachchi
Omali Pitiyarachchi
MFMichael Friedlander
Michael Friedlander
JJJames J. Java
James J. Java
JCJohn K. Chan
John K. Chan
DADeborah K. Armstrong
Deborah K. Armstrong
RMRobert S. Mannel
Robert S. Mannel
Patients with advanced epithelial ovarian cancer (EOC) alive without progression at a landmark time-point of 10 years from diagnosis are likely cured. We report the proportion of patients with Stage III EOC who were long-term disease-free survivors (LTDFS≥10 years) following either intraperitoneal (IP) or intravenous (IV) chemotherapy as well as the predictors of LTDFS. Data from 3 mature NRG/GOG trials (104, 114, 172) were analyzed and included demographics, clinicopathologic details, route of administration, and survival outcomes of patients living ≥10 years assessed according to the Kaplan-Meier method. Cox regression survival analysis was performed to evaluate independent prognostic predictors of LTDFS. Of 1174 patients randomized, 10-year overall survival (OS)was 26% (95% CI, 23–28%) and LTDFS ≥10 yearswas18% (95%CI, 16–20%). Patientswith LTDFS ≥10 years had amedian age of 54.6 years (p<0.001). Younger age (p< 0.001)was the only independent prognostic factor for LTDFS≥10 years onmultivariate Cox analysis. Approximately 18% of patients were LTDFS ≥10 years. They form the tail end of the survival curve and are likely cured. Our results provide a comparative benchmark to evaluate the impact of PARP inhibitors in 1st line maintenance trials on survival outcomes.

17 February 2023 in Translational Oncology
Verified
Journal Article
Open access
OPOmali Pitiyarachchi
Omali Pitiyarachchi
YLYeh Chen Lee
Yeh Chen Lee
Hao-Wen SimHao-Wen Sim
Hao-Wen Sim
SSSivatharsny Srirangan
Sivatharsny Srirangan
CMCristina Mapagu
Cristina Mapagu
MFMichael Friedlander
Michael Friedlander
Somatic pathogenic variants (PVs) in homologous recombination DNA repair (HR)-related genes found in high-grade serous ovarian carcinomas (HGSC) are not well-characterised in older patients (≥70 years). This may reflect low testing rates in older patients. Data from 1210 HGSC patients in AACR Project GENIE and 324 patients in an independent dataset INOVATe were analysed. Cases where somatic variants could be distinguished from germline variants were included, and analysis was restricted to those with a somatic TP53 variant, to ensure cases were HGSC. Of 1210 patients in GENIE, 27% (n = 325) were aged ≥70 years at testing. Patients with somatic-only PVs in BRCA2 were older compared with BRCA1 (median 71 vs 60 years, p = 0.002). Median age for 21 patients with somatic-only PVs in 11 other HR-related genes ranged from 40 to 67 years. In older patients, 7% (n = 22) had somatic BRCA1/2 PVs, and 1% (n = 2) had PVs other HR-related genes; this rate was not significantly different to younger patients (<70 years), 7% (n = 62) BRCA1/2 and 2% (n = 19) other HR-related genes (p = 0.36). The overall frequency of somatic BRCA1/2 PVs was similar in INOVATe (n = 25; 7.7%) and somatic-only BRCA2 PVs were again found in older patients compared with BRCA1 (median age: at testing, 70 vs 63 years; at diagnosis, 68 vs 60 years). The overall frequency of somatic-only PVs in HR-related genes was similar in older and younger patients with HGSC, highlighting the importance of somatic testing irrespective of age. Limiting somatic testing by age may exclude patients who could benefit from maintenance poly(ADP-ribose) polymerase (PARP) inhibitors.

19 December 2025 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
OPOmali Pitiyarachchi
Omali Pitiyarachchi
ATAaron C. Tan
Aaron C. Tan
TTTawasapon Thambamroong
Tawasapon Thambamroong
RJRogelio Velasco Jr
Rogelio Velasco Jr
YUYuji Uehara
Yuji Uehara
CYChanghoon Yoo
Changhoon Yoo
Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care Inequity

19 June 2022 in Internal Medicine Journal
Verified
Journal Article
Closed access
OPOmali Pitiyarachchi
Omali Pitiyarachchi
WWWenchang Wong
Wenchang Wong
MCMelvin Chin
Melvin Chin

15 November 2022 in Cancer Research
Verified
Journal Article
Open access
JKJohn Kokkinos
John Kokkinos
GSGeorge Sharbeen
George Sharbeen
KHKoroush S. Haghighi
Koroush S. Haghighi
JYJanet Youkhana
Janet Youkhana
ARAparna Raina
Aparna Raina
APand Phoebe A. Phillips
and Phoebe A. Phillips
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and new therapeutic strategies are urgently required. A key drug delivery barrier and promoter of tumor progression is the fibrotic and heterogeneous microenvironment of PDAC which is mainly orchestrated by stromal cancer-associated fibroblasts (CAFs). Thus, any novel therapeutic strategy should not only target PDAC cells but should also aim to inhibit the pro-tumor properties of the PDAC stroma. However, to accurately evaluate the clinical potential of novel PDAC therapeutics, preclinical models are required that closely mimic the heterogeneity and multicellular architecture of human disease. Aim: We aimed to investigate the therapeutic potential of novel functionalized benzopyrans (CRO-05 & CRO-67) in a patient-derived PDAC tumor explant model. Methods: We collected PDAC tumor samples from patients undergoing resection of their primary tumor. We cultured whole tumor explants (1-2mm diameter) on gelatin sponges. This model accurately maintains the multicellular tumor and stromal architecture of human PDAC [Kokkinos et al, Scientific Reports, 11,1941 (2021)]. Tumor explants were treated every 3 days with the racemic compound CRO-05 or its active enantiomer CRO-67 and explants were fixed in paraformaldehyde at day-12. Therapeutic response was assessed by immunohistochemistry for markers of tumor cells (cytokeratin), CAFs (α-Smooth Muscle Actin), cell-proliferation (Bromodeoxyuridine), and cell-death (TUNEL). Results: Treatment of human PDAC explants with CRO-05 resulted in reduced tumor cell frequency in 3/4 patients and in 4/4 patients, reduced CAF frequency, decreased cell-proliferation, and increased cell-death relative to controls. CRO-67 treatment in explants from 4/5 patients led to reduced tumor cell frequency, and in 5/5 patients, reduced CAF frequency, decreased cell-proliferation, and increased cell-death relative to controls. Conclusions: This work identifies the functionalized benzopyrans CRO-05 and CRO-67 as novel dual-cell therapeutics that potently inhibit both PDAC tumor cells and their surrounding CAFs and provides support for their clinical development as novel PDAC therapeutics. Citation Format: John Kokkinos, George Sharbeen, Koroush S. Haghighi, Janet Youkhana, Aparna Raina, Omali Pitiyarachchi, Quach Truong, Daniel Wenholz, Olivier Laczka, Naresh Kumar, David Goldstein, Phoebe A. Phillips. CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr C073.

25 August 2026 in ESMO Open
Verified
Journal Article
Open access
AWA.N.M. Wong
A.N.M. Wong
PFPaula Franco
Paula Franco
HSH.S. Sheikh
H.S. Sheikh
OPO. Pitiyarachchi
O. Pitiyarachchi
NPN. Prasongsook
N. Prasongsook
NCN. Cherny
N. Cherny
The European Society for Medical Oncology (ESMO) conducted a global survey on the availability, out-of-pocket costs (OPCs), and accessibility of cancer medicines in 2015, with an updated survey in 2023. The Asia-Pacific (APAC) region accounts for approximately half of global cancer-related deaths, yet substantial disparities persist in access to essential cancer medicines. A focused analysis of the 2023 ESMO global survey was undertaken to evaluate access trends specific to the APAC region. Data from the 2023 ESMO global survey were analysed to assess the availability, access, and OPC of cancer medicines in APAC countries, using the World Health Organization's Essential Medicines List as a benchmark. Countries included in the analysis were Australia, Taiwan (China), Japan, New Zealand, Republic of Korea, Singapore, China, Malaysia, Thailand, Bangladesh, Cambodia, India, Indonesia, Mongolia, Myanmar, Nepal, Papua New Guinea, Philippines, Vanuatu, and Vietnam. Selected case studies, including immunotherapy and oral targeted therapies, were used to explore access and regulatory approval timelines. A descriptive comparison of health technology assessment processes across APAC countries was also conducted. Availability and access to antineoplastic medicines in APAC remain limited, particularly in low- and middle-income countries. Although novel therapies are generally available, they often incur substantial OPC burdens on patients. The case studies reveal considerable delays in regulatory approval for both immunotherapy and targeted therapies across the region. Despite the introduction of innovative cancer therapies, substantial inequities in access and availability persist across APAC. Coordinated regional policies and streamlined regulatory processes may improve equitable access in the region.